Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method therefor, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.本發明提供內磺醯胺化合物及其使用方法,具體涉及如式I所示的新的具有異檸檬酸脫氫酶1(IDH1)抑制活性的化合物或其藥學上可接受的鹽、溶劑化物或水合物、其製備方法及包含其的藥物組合物。本發明還涉及所述化合物或其藥學上可接受的鹽、溶劑化物或水合物和包含其的藥物組合物治療IDH1突變誘發的癌症中的用途。